Early research (Phase 1)Study completedNCT02262910What this trial is testingStudy of ES414 in Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer Aptevo Therapeutics 35
Not applicableActive Not RecruitingNCT05844761What this trial is testingReal-time Motion Management During Prostate and Lung RadiotherapyWho this might be right forCancer of LungLung MetastasisCancer of Prostate Region Skane 132
Early research (Phase 1)WithdrawnNCT03110588What this trial is testingPhase I Trial of PACE for Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer University of Alabama at Birmingham
Early research (Phase 1)Study completedNCT00327288What this trial is testingSafety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer PatientsWho this might be right forNon-small Cell Lung CancerBreast CancerProstate Cancer AmpliMed Corporation 34
Testing effectiveness (Phase 2)Looking for participantsNCT06832774What this trial is testingExploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP PatientsWho this might be right forProstate Cancer Metastatic Disease Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 192
Not applicableApproved For MarketingNCT01606982What this trial is testingProvide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyWho this might be right forMetastatic Castration-Resistant Prostate Cancer Astellas Pharma Global Development, Inc.
Early research (Phase 1)Active Not RecruitingNCT03523442What this trial is testingAndrogen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstatic Neoplasms Janssen Research & Development, LLC 19
Early research (Phase 1)Study completedNCT04628988What this trial is testingCC-90011 and Comparators in Participants With Prostate CancerWho this might be right forProstatic Neoplasms Celgene 6
Not applicableWithdrawnNCT03596710What this trial is testingImage-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer Jonsson Comprehensive Cancer Center
Not applicableStudy completedNCT03329742What this trial is testingSipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate CancerWho this might be right forProstate Cancer Recurrent Indiana University 2
Early research (Phase 1)Study completedNCT03412786What this trial is testingBcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node MetastasesWho this might be right forProstate Cancer Herlev Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04253262What this trial is testingCopanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer Brown University 13
Testing effectiveness (Phase 2)Looking for participantsNCT07181161What this trial is testingStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer AstraZeneca 283
Testing effectiveness (Phase 2)Looking for participantsNCT06970119What this trial is testingA Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate CancerWho this might be right forProstate Cancer Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Early research (Phase 1)Ended earlyNCT04033328What this trial is testingStudy of ORIC-101 in Combination With EnzalutamideWho this might be right forProstatic Neoplasms ORIC Pharmaceuticals 41
Early research (Phase 1)Looking for participantsNCT05613894What this trial is testingDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer University of Utah 33
Not applicableLooking for participantsNCT06600802What this trial is testingIntrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerWho this might be right forCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA) Centre Jean Perrin 120
Not applicableLooking for participantsNCT06700057What this trial is testingClinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.Who this might be right forProstate CancerMetastasis Institut Bergonié 50
Large-scale testing (Phase 3)Study completedNCT00002881What this trial is testingFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerWho this might be right forProstate Cancer Eastern Cooperative Oncology Group
Not applicableUnknownNCT04851639What this trial is testingThe Wolverhampton Assessment Tool, a Tool for Patient-reported Wellbeing in the Context of Prostate CancerWho this might be right forAdvanced Prostate Carcinoma University of Wolverhampton 50